They involve increasing ligand secretion through well-known upstream signaling pathways that regulate the production of CXCR3 ligands, such as the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and histone methyltransferase enhancer of zeste homolog 2 (EZH2) pathways, within tumor cells in an autocrine manner. The gene discussed is CXCR3; the disease is neoplasm.